HEK293/Human FOLR1 Stable Cell Line
描述（Description）
The HEK293/Human FOLR1 Stable Cell Line was engineered to express the receptor full length human FOLR1 (Gene ID: 2348), used to mimic cancer target cells. Surface expression of Human FOLR1 was confirmed by flow cytometry.
應(yīng)用說明（Application）
Useful for cell-based FOLR1 binding assay
生長特性（Growth Properties）
Adherent
篩選標(biāo)記（Selection Marker）
Puromycin (2 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： FOLR1穩(wěn)定細(xì)胞系;FOLR1細(xì)胞系;FOLR1細(xì)胞株;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。